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Sepsis is one of the leading causes of death in hospitalised 
patients worldwide. It causes more casualties than prostate 
cancer, breast cancer and HIV/AIDS combined.1 Over the 
last decades multiple clinical trials searching for an effective 
pharmacological treatment for sepsis have failed to identify ‘a 
magic bullet’ that significantly improves the outcome in patients 
suffering from sepsis. Moreover, several interventions that 
appeared to exert beneficial effects were not confirmed to be 
effective in randomised controlled trials.2-4 It seems that sepsis 
suffers from more negative clinical trials than any other disease.
Yet, despite the absence of a single effective treatment, in March 
of this year Kaukonen and co-workers published a retrospective, 
observational study in which they reported an overall decrease 
in sepsis mortality in Australia and New Zealand.5 Over one 
decade, in 171 participating ICUs, more than 100,000 patients 
were included. In more detail, absolute mortality in severe 
sepsis patients decreased from 35.0% in 2000 to 18.4% in 2012. 
This represents an overall decrease in mortality of 16.7%, 
with a gradual decline in mortality of 1.3% annually. This is a 
compelling epidemiological study and on first sight one may 
conclude that the prognosis for sepsis patients has improved 
considerably. However, caution is needed in the interpretation 
of observational studies. Several other possible explanations of 
the observed effects need to be addressed. Similar to discussions 
related to population-wide screening for cancer, increased 
awareness may also lead to an earlier diagnosis for sepsis patients. 
The subsequent less advanced disease may suggest a better 
survival time (and thus lower mortality), while this may not 
be truly the case. Indeed, in Kaukonen’s sepsis study, over time 
fewer patients suffered from concomitant respiratory failure (60 
vs 37%) or renal failure (30 vs 25%), important covariates that 
are mostly present at ICU admission and are known to influence 
outcome. Also, according to the reported quartiles of APACHE 
III scores as a measure of their severity of illness, less sick 
patients were admitted to the ICU over time and the incidence 
of urosepsis (with a better prognosis than sepsis from other 
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sites of infection) increased. These differences in case mix may 
explain the observed improved outcome to an important extent 
and statistical adjustment for only APACHE score might be 
insufficient to correct for this. Of interest, the observed decrease 
in mortality was most pronounced in less severely ill, younger, 
urosepsis patients without other comorbidities. Moreover, a 
similar improvement in outcome was observed in non-septic 
ICU patients, suggesting that it is not a sepsis-specific treatment 
that accounts for the improvement, but possibly earlier referral 
to an ICU or an overall improvement of ICU quality of care over 
time. Nevertheless, while it remains unclear whether changes in 
case mix, changes in diagnostic procedures or improvements in 
the treatment of sepsis contribute to the decline in case fatality, 
similar mortality rates have been found in other recent sepsis 
studies. For example, Angus et al. recently reported a 60-day 
mortality of septic shock of approximately 20%.6
In the Netherlands, a significant improvement in compliance 
to the resuscitation bundle of the Surviving Sepsis Campaign 
between 2005 and 2009 was observed, associated with a 
decrease in mortality.7 Again, with the data available, it was 
not possible to adjust for other relevant covariates or patient 
characteristics. Recently, interesting data available from 
the Netherlands Intensive Care Evaluation database were 
reported.8 In this Dutch multicentre cohort study, a decrease in 
mortality of 5.8% over 3.5 years was found in sepsis patients in 
those hospitals that participated in the national surviving sepsis 
campaign. In hospitals that did not participate, or in patients 
who were not screened for sepsis, this improvement was not 
observed. So, in contrast to the Kaukonen study, the beneficial 
effect appears to be most pronounced in sepsis patients, and 
adjustments for age, gender, admission type, severity of illness 
and location of sepsis diagnosis were made. Also, reported 
severity of illness did not change significantly during the study 
period, suggesting that the observed change in outcome is not 
a result of earlier ICU admission. While a similar decrease in 
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sepsis mortality was observed as in the Kaukonen study, the 
additional finding of a clear association with adherence to the 
guideline bundles is of importance. Even more so, adherence to 
the resuscitation bundle was not associated with the observed 
decrease in mortality, in accordance with the recent ProCESS 
trial,6 while adherence to the management bundle was. This 
strongly suggests that predominantly ICU treatments for sepsis 
patients are beneficial. Taken together, these studies indicate 
that the prognosis of sepsis is slowly, but steadily, improving. 
In summary, the steady decline of mortality rate indicates 
that a single sepsis-specific therapy does not account for the 
improved prognosis of sepsis patients over time. It appears that 
both improved awareness and screening of sepsis, as well as 
improved general ICU quality of care, account for the observed 
improvements in outcome. While some may be disappointed 
that the quest for the ‘magic bullet’ has not yet been successful, 
the observation that good clinical care has a major clinical 
impact is definitely reassuring. 
References
1. World Sepsis Day Organisation [internet] 2014. [Cited June 3 2014] Available 
from http://www.world-sepsis-day.org/.
2. Sprung CL, Annane D, Keh D, et al. CORTICUS Study Group. Hydrocortisone 
therapy for patients with septic shock. N Engl J Med. 2008;358:111-24.
3. Ranieri VM, Thompson BT, Barie PS, et al. PROWESS-SHOCK Study Group. 
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 
2012;366:2055-64.
4. Finfer S, Chittock DR, Su SY, et al. NICE-SUGAR Study Investigators. Intensive 
versus conventional glucose control in critically ill patients. N Engl J Med. 
2009;360:1283-97.
5.  Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to 
severe sepsis and septic shock among critically ill patients in Australia and New 
Zealand, 2000-2012. JAMA. 2014;311:1308-16.
6.  Yealy DM, Kellum JA, Huang DT, et al. ProCESS Investigators. A randomized trial 
of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683-93.
7.  Tromp M, Tjan DH, van Zanten AR, et al. The effects of implementation of the 
Surviving Sepsis Campaign in the Netherlands. Neth J Med. 2011;69:292-8.
8.  Van Zanten AR, Brinkman S, Arbous MS, Abu-Hanna A, Levy MM, de Keizer NF; 
for The Netherlands Patient Safety Agency Sepsis Expert Group. Guideline 
Bundles Adherence and Mortality in Severe Sepsis and Septic Shock. Crit Care 
Med. 2014. [Epub ahead of print] PMID: 24670937. 
Onderzoeksvoorstellen voor NVIC-Astellas Research Grant 2014
Alle leden van de NVIC worden van harte uitgenodigd om een onderzoeksvoorstel in te dienen voor de NVIC-Astellas 
Research Grant 2014. Aan deze prijs is een geldbedrag van 7500 euro verbonden. Het onderwerp van het onderzoek 
dient gerelateerd te zijn aan de intensive care. De NVIC-Astellas Research Grant 2014 wordt aan de indiener van 
het winnende onderzoeksvoorstel uitgereikt tijdens de lunch op de tweede dag van het NVIC Najaarscongres, op 
19 september a.s. 
Op de website van de vereniging (www.nvic.nl) vindt u de instructie voor het inzenden van het onderzoeksvoorstel. 
Alleen onderzoeksvoorstellen die voldoen aan het genoemde format, zullen in behandeling worden genomen. Uw 
onderzoeksvoorstel kunt u mailen naar secretariaat@nvic.nl. De deadline voor het indienen is 1 september 2014. De 
organisatie en jurering is in handen van de NVIC Congrescommissie.
10622_bw_njcc_2014_04_13.indd   3 16-07-14   11:10
